Geriatrics
From the Journals
No cognitive benefit from meditation, learning a language?
The findings contradict the researchers’ earlier work that found mindfulness meditation boosted cognitive function in older adults with subjective...
Latest News
New consensus on biomarkers for diagnosis of neurocognitive disorders
Reducing the options available to clinicians when making a differential diagnosis into the current algorithm is a pragmatic approach.
From the Journals
SSRI improves cognition, major depression in early dementia
Improvements in depressive symptoms were irrespective of dementia type.
News
Altered gut bacteria a biomarker of preclinical Alzheimer’s?
It’s not known whether the gut is influencing the brain, or the brain is influencing the gut, “but this association is valuable to know in either...
From the Journals
Muscle fat: A new risk factor for cognitive decline?
“Increasing adiposity – or fat deposition – in skeletal muscles predicted faster cognitive decline, irrespective of demographics or other disease...
Latest News
Flavanol supplement improves memory in adults with poor diets
The evidence shows that consuming these nutrients might be associated with the hippocampal-dependent memory component of cognitive aging.
Latest News
Potential new treatment for REM sleep behavior disorder
The disorder can signal risk for synucleinopathies, a group of neurological conditions such as Parkinson's disease that involve the formation of...
From the Journals
Internet use a modifiable dementia risk factor in older adults?
“Online engagement can develop and maintain cognitive reserve – resiliency against physiological damage to the brain – and increased cognitive...
FDA/CDC
FDA approves first drug to treat Alzheimer’s agitation
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease.”
From the Journals
Hearing aids are a ‘powerful’ tool for reducing dementia risk
“The evidence is building that hearing loss may be the most impactful modifiable risk factor for dementia in mid-life.”
Conference Coverage
Donanemab bests aducanumab in head-to-head Alzheimer’s trial
Nearly 40% of patients treated with donanemab had amyloid clearance at 6 months compared with less than 2% of those who received aducanumab.